Nadir Meme Tümörleri
Özet
Meme kanseri, kadınlarda en sık teşhis edilen ve heterojen özellikler gösteren bir malignite grubudur. En yaygın tipler invaziv duktal ve lobüler karsinomlar iken, olguların küçük bir kısmını nadir meme tümörleri oluşturmaktadır. Bu nadir varyantlar; müsinöz, tübüler, medüller, tubulolobüler, mikropapiller, metaplastik, adenoid kistik, sekretuar ve apokrin karsinomlar ile malign filloid tümörleri içermektedir. Müsinöz, tübüler ve adenoid kistik karsinomlar genellikle infiltrasyon yapan duktal karsinomlara kıyasla daha olumlu bir prognoza sahiptir. Buna karşın, mikropapiller karsinom gibi bazı türler agresif seyirli olup lenf nodu metastazına yüksek eğilim gösterir. İmmünohistokimyasal ve moleküler profiller tümör tiplerine göre ciddi farklılıklar arz etmektedir; örneğin sekretuar karsinom üçlü negatif olmasına rağmen indolent seyirlidir ve özgün bir gen füzyonu içerir. Malign filloid tümörler ise fibroepitelyal kökenli olup yönetimlerinde hormon tedavisinin yeri yoktur ve sistemik kemoterapide yumuşak doku sarkomu protokolleri uygulanır. Bu özgün neoplazilerin nadir görülmesi, geniş çaplı randomize klinik çalışmaların yapılmasını engellemekte, mevcut verilerin çoğunu olgu sunumları ve küçük serilerle sınırlı kılmaktadır. Dolayısıyla, bu heterojen grubun optimal klinik yönetimi ve tedavisine yönelik standart ve net rehberler henüz tam olarak oluşturulamamıştır.
Breast cancer is the most frequently diagnosed malignancy in women, characterized by a highly heterogeneous group of tumors with distinct pathological features. While invasive ductal and lobular carcinomas represent the vast majority of cases, a small percentage consists of rare breast tumors. These rare variants encompass mucinous, tubular, medullary, tubulolobular, micropapillary, metaplastical, adenoid cystic, secretory, and apocrine carcinomas, as well as malignant phyllodes tumors. Mucinous, tubular, and adenoid cystic carcinomas generally exhibit a more favorable prognosis compared to ordinary invasive ductal cancers. In contrast, certain types like micropapillary carcinoma are particularly aggressive with a high propensity for lymph node metastasis. Immunohistochemical and molecular profiles vary significantly among these types; for instance, secretory carcinoma is an indolent triple-negative tumor harboring a specific gene fusion. Malignant phyllodes tumors are fibroepithelial lesions where hormone therapy is ineffective, and systemic chemotherapy follows soft tissue sarcoma protocols. Due to the low incidence of these specific neoplasms, conducting large-scale randomized clinical trials remains challenging, restricting available medical literature to small case series and reports. Consequently, definitive guidelines for the optimal clinical management and tailored treatment of these heterogeneous malignancies are still lacking.
Referanslar
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7.
Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press Breast Cancer Research 2004;6:133.
Northridge ME, Rhoads GG,Wartenberg D, et al. The importance of histologic type on breast cancer survival. J Clin Epidemiol 1997;50:283-90.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on April 14, 2020).
Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:152.
Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111:541.
Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003; 163:2149.
Liu GF, Yang Q, Haffty BG, Moran MS. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 2009; 75:1304.
Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002; 34:309.
Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 2005; 62:1040.
Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol 2001; 32:583.
Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007; 14:166.
Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. J Clin Oncol 2005; 23:7827.
Behranwala KA, Nasiri N, Abdullah N, et al. Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 2003; 29:386.
Dave G, Cosmatos H, Do T, et al. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys 2006; 64:771.
Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol 1999; 71:220.
Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol 2013; 44:301.
McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA 1966; 195:388.
Horowitz DP, Sharma CS, Connolly E, et al. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast 2012; 21:350.
Hoda RS, Brogi E, Pareja F, et al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology 2019; 75:213.
Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010; 34:599.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.
Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010; 23:644.
D'Arcy C, Quinn CM. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol 2019; 72:7.
Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89:1502.
Tavassoli FA, Devilee P. and genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, IARC Press, Lyons 2003. p.99.
Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008; 70:492.
Burton GV, Hart LL, Leight GS Jr, et al. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer 1989; 63:2088.
Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003; 30:413.
